

VERSION WITH MARKINGS TO SHOW CHANGES MADE**In the Specification:**

On page 1, after line 5, insert:

--CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a National Stage of International Application No. PCT/AU99/01108, filed December 13, 1999, which claims priority to Australian Patent Application No. PP 7653, filed December 11, 1998.--

In the Claims

There are two Claim 13's, please cancel the first Claim 13.

Please amend the following claims:

1. (Amended) A method of treatment of an existing [papillomavirus (] PV [)] infection [which includes the step of administration of PV VLPs selected from the group consisting of] comprising: administering a composition comprising (a) PV L1 VLPs [and] or (b) PV L1[L2] VLPs and PV L2 VLPs to a patient suffering from the PV infection.
2. (Amended) [A] The method of treatment [as claimed in] according to Claim 1 , wherein the PV infection is characterised by the presence of epithelial lesions.
3. (Amended) [A] The method of treatment [as claimed in] according to Claim 2 , wherein the epithelial lesions are selected from the group consisting of palmar warts, planter warts, ano-genital warts, flat and planar warts of the skin and muscosal surfaces, CIN, equine sarcoid and replicating or vegetative PV infection.
4. (Amended) [A] The method of treatment [as claimed in] according to Claim 3 , wherein the [PV infection is] epithelial lesions are genital warts caused by HPV 6, 11, 34, 39, 41 [-44 and 51-] 42, 43, 44 , 51, 52, 53, 54, or 55.
5. (Amended) [A] The method of treatment [as claimed in] according to Claim 4 , wherein the genital warts are caused by HPV 6 [and] or HPV 11.

6. (Amended) A method of [treatment as claimed in any preceding claim wherein the VLPs are produced by] producing a PV VLP comprising: (a) cloning [the] one or more PV [L1 gene] VLP genes into a [suitable] vector and (b) expressing the [corresponding conformational coding sequence for L1] one or more PV VLP genes in an eukaryotic cell transduced by the vector.
7. (Amended) [A] The method [of treatment as claimed in] according to Claims 1-5 [wherein the VLPs are produced by] ,further comprising: cloning the PV L1 [and] or PV L2 gene[s] into a [suitable] vector and expressing the [corresponding conformational coding sequence for L1 and L2] PV L1 or PV L2 gene in [an eukaryotic] a host cell [transduced by the vector] .
8. (Amended) [A] The method [as claimed in] according to Claim 6 [or 7] , wherein the one or more PV VLP genes comprise (i) a PV L1 VLP gene or [L1 and L2 genes are inserted into] (ii) a PV L1 VLP gene and a PV L2 VLP gene, wherein the vector is an expression vector [containing flanking sequences to form a gene construct and the resulting recombinant DNA is co-transfected with wild type baculovirus DNA into] , wherein the host cell is a cell from a permissive cell line.
9. (Amended) [A] The method [as claimed in] according to Claim 6 [or 7] , wherein the permissive cell line is a Sf9 insect cell[s] line and the expression vector is a baculovirus expression vector.
10. (Amended) [A] The method [as claimed in] according to Claim 8 , wherein the permissive cell line is a procaryotic cell line.
11. (Amended) [A] The method [as claimed in any preceding claim] according to Claim 1, wherein the concentration of PV L1 VLPs or PV L1 VLPs and PV L2 VLPs administered to the patient is 0.5-20 µg.
12. (Amended) [A] The method [as claimed in] according to Claim 11 , wherein the concentration is 1-10 µg.

13. (Amended) [A] The method [of treatment as claimed in] according to Claim 11 or 12 , wherein [dosages of PV VLPs are given] the composition is administered 3-6 times over a period of 8-16 weeks.
14. (Amended) [A] The method [of treatment as claimed in] according to Claim 11 , wherein [dosages of PV VLPs are} the composition is administered 3-6 times over a period of 2-4 weeks.
15. (Amended) A method of immunization against HPV11 infection[s by administration of] comprising administering HPV6 VLPs to a patient.
16. (Amended) [A] The method [as claimed in] according to Claim 15 , wherein the HPV6 VLPs are HPV6b VLPs [are administered to the patient] .
17. (Amended) [A] The method [as claimed in] according to Claim 15 or 16 , wherein the concentration of the HPV6 VLPs are 0.5-20 µg.
18. (Amended) [A] The method [as claimed in] according to Claim 17 , wherein the concentration of the HPV6 VLPs are 1-10 µg.
19. (Amended) [A] The method [as claimed in] according to Claim 17 [or 18] , wherein [dosages of] the HPV6 VLPs are [given] administered 3-6 times over a period of 8-16 weeks.
20. (Amended) [A] The method [as claimed in] according to Claim 17 [or 18] , wherein [dosages of] the HPV6 VLPs are [given] administered 3-6 times over a period of 24 weeks.
21. (Amended) A method of immunization against HPV6 infections [by administration of] comprising administering HPV11 VLPs to a patient.
22. (Amended) [A] The method [of immunization as claimed in] according to Claim 21 , wherein the concentration of the HPV11 VLPs is 0.5-20 µg.
23. (Amended) [A] The method [of immunization as claimed in] according to Claim 22 ,

wherein the concentration of the HPV11 VLPs is 1-10 µg.

24. (Amended) [A] The method [of immunization as claimed in] according to Claim 22 or 23 , wherein [dosages of] the HPV11 VLPs are [given] administered 3-6 times over a period of 8-16 weeks.

25. (Amended) [A] method [of immunization as claimed in] according to Claim 22 or 23 , wherein [dosages of] the HPV11 VLPs are [given] administered 3-6 times over a period of 2-4 weeks.

26. (Amended) A method of treatment of an existing [PV] papillomavirus infection [which includes the step of administration of PV] comprising administering papillomavirus VLPs without adjuvant to a patient suffering from the [PV infections] papillomavirus infection .

27. (Amended) [A] The method [of treatment as claimed in] according to Claim [27] 26, wherein the [PV] papillomavirus VLPs are chimeric.

28. (Amended) [A] The method [of treatment as claimed in] according to Claim 26 , wherein the [PV] papillomavirus VLPs comprise E protein.

29. (Amended) [A] The method [of treatment as claimed in] according to Claim 1 , wherein the [PV VLPs include administering] composition further comprises an adjuvant.

30. (Amended) [A] The method [of treatment as claimed in] according to Claim 29 , wherein the adjuvant is one that induces cellular responses.

31. (Amended) [A] The method [of treatment as claimed in] according to Claim 30 , wherein the adjuvant[s are] is selected from the group consisting of (1) lipid A and derivatives, (2) Quillaia saponins and derivatives, (3) mycobacteria and components or derivatives therefrom [and] is (4) IL 12, GMCSF, other Th1 inducing cytokines and (5) oxidized mannan and analogues thereof.

Please add the following new claim:

- 32. (New) The method according to Claim 1, wherein the composition lacks an adjuvant.-

-